IL‐2 modulates Th2 cell responses to glucocorticosteroid: A cause of persistent type 2 inflammation?
Abstract Background Glucocorticosteroids (GCs) are the main treatment for asthma as they reduce type 2 cytokine expression and induce apoptosis. Asthma severity is associated with type 2 inflammation, circulating Th2 cells and higher GC requirements. Objective The aim of this study was to assess whe...
Main Authors: | Tharsan Kanagalingam, Lauren Solomon, Meerah Vijeyakumaran, Nami Shrestha Palikhe, Harissios Vliagoftis, Lisa Cameron |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-09-01
|
Series: | Immunity, Inflammation and Disease |
Subjects: | |
Online Access: | https://doi.org/10.1002/iid3.249 |
Similar Items
-
Comparative efficacy of glucocorticoid receptor agonists on Th2 cell function and attenuation by progesterone
by: Alexander Luchak, et al.
Published: (2020-10-01) -
Protease-activated receptor-2: Role in asthma pathogenesis and utility as a biomarker of disease severity
by: Vivek Dipak Gandhi, et al.
Published: (2022-07-01) -
Dupilumab improve acquired reactive perforating collagenosis characterized by type 2 inflammation
by: Ben Liu, et al.
Published: (2023-08-01) -
Challenges in severe asthma: Do we need new drugs or new biomarkers?
by: Adil Adatia, et al.
Published: (2022-09-01) -
IL-4 Is a Key Requirement for IL-4- and IL-4/IL-13-Expressing CD4 Th2 Subsets in Lung and Skin
by: Melanie Sarah Prout, et al.
Published: (2018-06-01)